BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19097599)

  • 1. Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
    Chang H; Shih LY
    Chang Gung Med J; 2008; 31(5):510-4. PubMed ID: 19097599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
    Al-Kali A; Farooq S; Tfayli A
    J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour lysis syndrome with acute renal failure during imatinib therapy.
    Ali R; Ozkalemkas F; Ozkan A; Ozcelik T; Ozkocaman V; Akdag I; Ozan U; Tunali A
    Leuk Res; 2007 Apr; 31(4):573-4. PubMed ID: 16782190
    [No Abstract]   [Full Text] [Related]  

  • 4. Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib.
    Liapis K; Apostolidis J; Charitaki E; Panitsas F; Harhalakis N; Nikiforakis E
    Ann Pharmacother; 2008 Dec; 42(12):1882-6. PubMed ID: 19017824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
    François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
    Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea and splenic irradiation-induced tumour lysis syndrome: a case report and review of the literature.
    Chen SW; Hwang WS; Tsao CJ; Liu HS; Huang GC
    J Clin Pharm Ther; 2005 Dec; 30(6):623-5. PubMed ID: 16336296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Dann EJ; Fineman R; Rowe JM
    J Clin Oncol; 2002 Jan; 20(1):354-5. PubMed ID: 11773197
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
    Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
    Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irreversible sensorineural hearing loss due to Imatinib.
    Attili VS; Bapsy PP; Anupama G; Lokanatha D
    Leuk Res; 2008 Jun; 32(6):991-2. PubMed ID: 18221994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
    Khouri S; Kotliroff A; Lishner M; Amital H
    Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
    [No Abstract]   [Full Text] [Related]  

  • 11. [Imatinib-induced DRESS].
    Goldman J; Duval-Modeste AB; Lambert A; Contentin N; Courville P; Musette P; Joly P
    Ann Dermatol Venereol; 2008 May; 135(5):393-6. PubMed ID: 18457727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.
    Busuttil DP
    Int J Lab Hematol; 2008 Feb; 30(1):68-70. PubMed ID: 18190471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catastrophic tumour lysis syndrome following single dose of imatinib.
    Keane C; Henden A; Bird R
    Eur J Haematol; 2009 Mar; 82(3):244-5. PubMed ID: 19067739
    [No Abstract]   [Full Text] [Related]  

  • 14. [The tumor lysis syndrome: case report and review of the literature].
    Galesić K; Sabljar-Matovinović M; Morović-Vergles J; Minigo H; Jaksić B
    Lijec Vjesn; 1990; 112(3-4):99-102. PubMed ID: 2204777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib: new indication. New indications, but not robust evidence.
    Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute tumor lysis syndrome complicating conditioning therapy for bone marrow transplantation in a patient with chronic lymphocytic leukemia.
    Nomdedéu J; Martino R; Sureda A; Huidobro G; López R; Brunet S; Domingo-Albós A
    Bone Marrow Transplant; 1994 May; 13(5):659-60. PubMed ID: 8054919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment.
    Brazzelli V; Roveda E; Prestinari F; Barbagallo T; Bellani E; Trevisan V; Rona C; Locatelli F; Zecca M; Borroni G
    Pediatr Dermatol; 2006; 23(2):175-8. PubMed ID: 16650231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute lymphoblastic leukemia complicated with tumor lysis syndrome--four cases report].
    He H; Li C; Han M
    Zhonghua Xue Ye Xue Za Zhi; 1999 Jun; 20(6):310-2. PubMed ID: 11721390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.